

Certificate of Analysis

ErbB2, active

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-939, 14-939-K, 14-939M

Parent Lot # D13NP005N

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialing runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialing run.

Product Description: C-terminal 6His-tagged, recombinant, human ErbB2 amino acids 676-end expressed by baculovirus in Sf21 insect cells. Purified using immobilized metal affinity chromatography.

Purity 85% by SDS-PAGE and Coomassie blue staining. MW = 69kDa.

Specific Activity (Parent lot# D13NP005N):

361U/mg, where one unit of ErbB2 activity is defined as 1nmol phosphate incorporated into 0.1mg/ml poly(Glu, Tyr) (4:1) per minute at 30°C with a final ATP concentration of 100µM.

Formulation: 1.871mg/ml of enzyme in 50mM Tris/HCl pH7.5, 150mM NaCl, 0.5mM EDTA, 0.01% CHAPS, 50% glycerol, 2mM DTT. Frozen solution.


Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled microcentrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 4–32ng of this lot of enzyme phosphorylated 0.1mg/ml poly(Glu, Tyr) (4:1) in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed identity as ErbB2 with the translated sequence listed on page three.



Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

- 1. 5 x Reaction Buffer:** 40mM MOPS/NaOH pH7.0, 1mM EDTA
- 2. Poly(Glu, Tyr) (4:1):** Use at a final assay concentration of 0.1mg/ml. Prepare a 1mg/ml stock and add 2.5µl of stock per assay point.
- 3. Manganese Chloride:** Use at a final assay concentration of 5mM. Prepare a 100mM stock and add 1.25µL per well.
- 4. ErbB2, active:** Dilute with 20mM MOPS/NaOH pH7.0, 1mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 4-32ng per assay point.
- 5. [γ -³³P]ATP:** 2.5 x MgAc/[γ -³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ -³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required).

Assay Procedure (96 well plate format):

1. Add 5µl of 5 x reaction buffer per assay to wells.
2. Add 2.5µl of **poly(Glu,Tyr) (4:1)**.
3. Add 1.25µL 100mM manganese chloride.
4. Add 3.75µl of dH₂O.
5. Add **2.5µl (4–32ng) ErbB2, active**.
6. Add 10µl of diluted [γ -³³P]ATP mixture.
7. Incubate for 10 minutes at 30°C.
8. Stop the reaction by adding 5µl of 3% phosphoric acid.
9. Transfer a 10µl aliquot onto the appropriate area of a **Filtermat A**.
10. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
11. Wash the filtermat once for 2 minutes with methanol.
12. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
13. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1µl of 30% phosphoric acid.

Certificate of Analysis

ErbB2 Sequence Information

<u>Protein</u>	human ErbB2
<u>Tags</u>	C-terminal 6His
<u>Native sequence</u>	K19 and V598 of the recombinant protein are equivalent to K676 and V1255 of human ErbB2 respectively.
<u>Accession number</u>	GenBank NM_004448 The recombinant protein contains the amino acid substitution G778D with reference to GenBank NM_004448. The G778D mutation has been shown to promote folding of the recombinant protein into an active conformation (Fan <i>et al</i> , J. Biol. Chem. 283 , 1588-1596, 2008).

Recombinant ErbB2 amino acid sequence:

```

1  MLVPRGSPWI  RNSKAYVDKR  RQQKIRKYTM  RRLQLQETELV  EPLTPSGAMP  NQAQMRILKE
61  TELRKVKVLG  SGAFGTVYKG  IWIPDGENVK  IPVAIKVLRE  NTSPKANKEI  LDEAYVMAGV
121 DSPYVSRLLG  ICLTSTVQLV  TQLMPYGCLL  DHVRENRL  GSQDLLNWC  M  QIAKGMSYLE
181 DVRLVHRDLA  ARNVLVKSPN  HVKITDFGLA  RLLDIDET  EY  HADGGKVPIK  WMALESILRR
241 RFTHQSDVWS  YGVTWELMT  FGAKPYDGIP  AREIPDLLEK  GERLPQPPIC  TIDVYMIMVK
301 CWMIDSECRP  RFRELVSEFS  RMARDPQRFV  VIQNE  DLGPA  SPLDSTFYRS  LLEDDDMGDL
361 VDAEEYLVPQ  QGFFCPDPAP  GAGGMVHHRH  RSSSTRSGGG  DLTLGLEPSE  EEAPRSPLAP
421 SEGAGSDVFD  GDLGMGAAKG  LQSLPTHDP  S  PLQRYSEDPT  VPLPSETDGY  VAPLTCSPQP
481 EYVNQPDVRP  QPPSPREGPL  PAARPAGATL  ERPKTLSPGK  NGVVKDVFAF  GGAVENPEYL
541 TPQGAAPQP  HPPPAFSPAF  DNLYYWDQDP  PERGAPPSTF  KGTPTAENPE  YLGLDVPVCS
601 RHASGTDDYD  IATTHHHHHH

```

Recombinant ErbB2 nucleotide sequence:

```

1  atgttggtcc  cgcgtggctc  gccgtggatc  cgtaactcga  aagcctacgt  cgacaagcga
61  cggcagcaga  agatccggaa  gtacacgatg  cggagactgc  tgcaggaaac  ggagctggtg
121 gagccgctga  cacctagcgg  agcgatgccc  aaccaggcgc  agatgcggat  cctgaaagag
181 acggagctga  ggaagtgaa  ggtgcttgg  tctggcgctt  ttggcacagt  ctacaagggc
241 atctggatcc  ctgatgggga  gaatgtgaaa  attccagtgg  ccatcaaagt  gttgagggaa
301 aacacatccc  ccaaagccaa  caaagaaatc  ttagacgaag  catacgtgat  ggctgggtg
361 gactccccat  atgtctcccg  ccttctgggc  atctgcctga  catccacggt  gcagctggtg
421 acacagctta  tgccctatgg  ctgcctctta  gaccatgtcc  gggaaaaccg  cggacgcctg
481 ggctcccagg  acctgctgaa  ctgggtgatg  cagattgcca  aggggatgag  ctacctggag
541 gatgtgcggc  tcgtacacag  ggacttggcc  gctcggaacg  tgctggtcaa  gagtcccaac
601 catgtcaaaa  ttacagactt  cgggctggct  cggctgctgg  acattgacga  gacagagtac
661 catgcagatg  ggggcaaggt  gcccatcaag  tggatggcgc  tggagtccat  tctccgcccg
721 cggttcacc  accagagtga  tgtgtggagt  tatggtgtga  ctgtgtggga  gctgatgact
781 tttggggcca  aacctacga  tgggatccca  gcccgggaga  tccctgacct  gctggaaaag
841 ggggagcggc  tgcccagcc  ccccatctgc  accattgatg  tctacatgat  catgtgcaaa
901 tgttggtatg  ttgactctga  atgtcggcca  agattccggg  agttggtgtc  tgaattctcc
961 cgcattggcca  gggaccccc  gcgctttgtg  gtcatccaga  atgaggactt  gggcccagcc
1021 agtcccttgg  acagcacctt  ctaccgctca  ctgctggagg  acgatgacat  gggggacctg
1081 gtggatgctg  aggagtatct  ggtaccccag  cagggcttct  tctgtccaga  cctgcccccg
1141 ggcgctgggg  gcatggtcca  ccacaggcac  cgcagctcat  ctaccaggag  tggcggtggg
1201 gacctgacac  taggctgga  gccctctgaa  gaggaggccc  ccaggtctcc  actggcacc
1261 tccgaagggg  ctggctccga  tgtatctgat  ggtgacctgg  gaatgggggc  agccaagggg
1321 ctgcaaagcc  tccccacaca  tgaccccagc  cctctacagc  ggtacagtga  ggacccccca

```

Certificate of Analysis

```
1381 gtaccctgc cctctgagac tgatggctac gttgcccccc tgacctgcag cccccagcct
1441 gaatatgtga accagccaga tgttcggccc cagccccctt cgccccgaga gggccctctg
1501 cctgctgccc gacctgctgg tgccactctg gaaaggccca agactctctc cccaggggaag
1561 aatggggtcg tcaaagacgt ttttgccttt gggggtgccg tggagaacct cgagtacttg
1621 acaccccagg gaggagctgc ccctcagccc caccctctc ctgccttcag cccagccttc
1681 gacaacctct attactggga ccaggaccca ccagagcggg gggctccacc cagcaccttc
1741 aaagggacac ctacggcaga gaaccagag tacctgggtc tggacgtgcc agtgtgttcg
1801 cgtcacgcct cgggcacgga cgattacgac attgccacca cgcacacca tcaccatcac
1861 taa
```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services.